Biodesix announces four presentations of health economic data highlighting cost saving potential of nodify lung® testing

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in four separate poster presentations at the ispor (international society for pharmaceutical and outcomes research) conference, providing evidence of the health economic benefits of the nodify cdt® and nodify xl2® tests in the management of pulmonary nodules. the posters, presented may 8-9, 2023, highlighted potential cost savin.
BDSX Ratings Summary
BDSX Quant Ranking